{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:15:17Z","timestamp":1762899317732},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clinthera.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T11:06:06Z","timestamp":1470222366000},"page":"1817-1824","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Elisabetta","family":"Malangone-Monaco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Varker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorie","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.07.004_bib1","unstructured":"American Cancer Society. What are the key statistics about prostate cancer? http:\/\/www.cancer.org\/cancer\/prostatecancer\/detailedguide\/prostate-cancer-key-statistics. Accessed February 12, 2016."},{"key":"10.1016\/j.clinthera.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/onc.2013.235","article-title":"Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis","volume":"33","author":"Yuan","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.clinthera.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756287213509677","article-title":"Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy","volume":"6","author":"Omlin","year":"2014","journal-title":"Ther Adv Urol"},{"issue":"1 Suppl 2","key":"10.1016\/j.clinthera.2016.07.004_bib17","first-page":"33","article-title":"Patient selection for oral chemotherapy","volume":"15","author":"Sharma","year":"2001","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clinthera.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1758834012458137","article-title":"The changing landscape in the treatment of metastatic castration-resistant prostate cancer","volume":"5","author":"El-Amm","year":"2013","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinthera.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2490-14-55","article-title":"Changing paradigms in management of metastatic castration resistant prostate cancer (mCRPC)","volume":"14","author":"Gupta","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.clinthera.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/cam4.576","article-title":"Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data","volume":"5","author":"Flaig","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.clinthera.2016.07.004_bib21","first-page":"185","article-title":"Treatment sequences and pharmacy costs of 2 new therapies for metastatic castration-resistant prostate cancer","volume":"8","author":"Ellis","year":"2015","journal-title":"American Health Drug Benefits"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816304465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816304465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T18:51:04Z","timestamp":1536519064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816304465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0149291816304465"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.07.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}